WHO recommends COVID-19 drug and urges transparency around pricing
(United Nations News) A highly successful COVID-19 therapy must be made available to more people, the World Health Organization (WHO) has said, calling for wider distribution and greater transparency surrounding its pricing.
WHO announced on Friday in Geneva that it has strongly recommended use of nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at the highest risk of hospital admission.
The oral antiretroviral drug was developed by Pfizer and is “the best therapeutic choice for high-risk patients to date,” the UN agency said.
“However, availability, lack of price transparency in bilateral deals made by the producer, and the need for prompt and accurate testing before administering it, are turning this life-saving medicine into a major challenge for low- and middle-income countries.”
Read more at: United Nations News